Startseite>>Analytical Standards>>Doxazosin-d8 (hydrochloride)

Doxazosin-d8 (hydrochloride)

Katalog-Nr.GC47268

An internal standard for the quantification of doxazosin

Products are for research use only. Not for human use. We do not sell to patients.

Doxazosin-d8 (hydrochloride) Chemische Struktur

Cas No.: 1219803-95-8

Größe Preis Lagerbestand Menge
500 μg
83,00 $
Auf Lager
1 mg
160,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Doxazosin-d8 is intended for use as an internal standard for the quantification of doxazosin by GC- or LC-MS. Doxazosin is a non-selective antagonist of α1-adrenergic receptors (α1-ARs; Kis = 3.16, 1, and 3.98 nM for α1A-, α1B-, and α1D-ARs, respectively).1 It inhibits norepinephrine-induced contractions in isolated rat aortic rings and human prostate strips with pA2 values of 8.8 and 8.2, respectively. Doxazosin inhibits phenylephrine-induced increases in blood pressure and prostatic pressure in anesthetized dogs (pA2 = 7.5 for both). Formulations containing doxazosin have been used in the treatment of benign prostatic hyperplasia and hypertension.

1.Kenny, B.A., Miller, A.M., Williamson, I.J.R., et al.Evaluation of the pharmacological selectivity profile of α1 adrenoceptor antagonists at prostatic α1 adrenoceptors: Binding, functional and in vivo studiesBr. J. Pharmacol.118(4)871-878(1996)

Bewertungen

Review for Doxazosin-d8 (hydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Doxazosin-d8 (hydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.